|Articles|June 1, 2003
- BioPharm International-06-02-2003
- Volume 2003 Supplement
- Issue 1
BioPharm International's Virus Inactivation Series: A Preface
Author(s)Shirley I. Miekka, William N. Drohan
by William N. Drohan, Clearant Inc. and Shirley I. Miekka
Advertisement
Articles in this issue
over 22 years ago
Part 1: Skin, Bone, and Cellsover 22 years ago
Part 4: Culture Media, Biotechnology Products, and Vaccinesover 22 years ago
Inactivation of Viruses: An Introduction to the Seriesover 22 years ago
Part 6: Inactivation Methods Grouped by Virusover 22 years ago
Part 5: Disinfectionover 22 years ago
Part 2: Red Blood Cells and PlateletsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
2
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
5
